Shareholder information

Here’s where you’ll find services and information for our shareholders, both UK and international.

 

Share price information >

See the latest share price, share price chart, and share price calculator.

ADR programme >

American Depositary Receipts for US shareholders.

Advisors and Investor contacts >

All the key contacts related to investing in Vernalis.

Analyst coverage >

What do the analysts who follow Vernalis say about the company?

Shareholder services >

Download change of address, stock transfer forms, etc.

Shareholder alert >

If you have received unsolicited contact regarding the purchase of your Vernalis shares please read this document. Download here

Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch